Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bridging Animal and Human Data in Pursuit of Vaccine Licensure.
Finch CL, Dowling WE, King TH, Martinez C, Nguyen BV, Roozendaal R, Rustomjee R, Skiadopoulos MH, Vert-Wong E, Yellowlees A, Sullivan NJ. Finch CL, et al. Among authors: yellowlees a. Vaccines (Basel). 2022 Aug 25;10(9):1384. doi: 10.3390/vaccines10091384. Vaccines (Basel). 2022. PMID: 36146462 Free PMC article. Review.
Systematic review and meta-analysis: the effects of fermented milk with Bifidobacterium lactis CNCM I-2494 and lactic acid bacteria on gastrointestinal discomfort in the general adult population.
Eales J, Gibson P, Whorwell P, Kellow J, Yellowlees A, Perry RH, Edwards M, King S, Wood H, Glanville J. Eales J, et al. Among authors: yellowlees a. Therap Adv Gastroenterol. 2017 Jan;10(1):74-88. doi: 10.1177/1756283X16670075. Epub 2016 Oct 10. Therap Adv Gastroenterol. 2017. PMID: 28286561 Free PMC article. Review.
Estimation of ELISA results using a parallel curve analysis.
Bursa F, Yellowlees A, Bishop A, Beckett A, Hallis B, Matheson M. Bursa F, et al. Among authors: yellowlees a. J Immunol Methods. 2020 Nov;486:112836. doi: 10.1016/j.jim.2020.112836. Epub 2020 Aug 20. J Immunol Methods. 2020. PMID: 32827492
A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN.
Leonard RC, Mansi JL, Keerie C, Yellowlees A, Crawford S, Benstead K, Matthew R, Adamson D, Chan S, Grieve R; Anglo-Celtic Collaborative Oncology Group. Leonard RC, et al. Among authors: yellowlees a. Ann Oncol. 2015 Dec;26(12):2437-41. doi: 10.1093/annonc/mdv389. Epub 2015 Sep 28. Ann Oncol. 2015. PMID: 26416895 Free article. Clinical Trial.
GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.
Leonard RCF, Adamson DJA, Bertelli G, Mansi J, Yellowlees A, Dunlop J, Thomas GA, Coleman RE, Anderson RA; Anglo Celtic Collaborative Oncology Group and National Cancer Research Institute Trialists. Leonard RCF, et al. Among authors: yellowlees a. Ann Oncol. 2017 Aug 1;28(8):1811-1816. doi: 10.1093/annonc/mdx184. Ann Oncol. 2017. PMID: 28472240 Free article. Clinical Trial.
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
Evans TR, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RC, Mansi JL. Evans TR, et al. Among authors: yellowlees a. J Clin Oncol. 2005 May 1;23(13):2988-95. doi: 10.1200/JCO.2005.06.156. J Clin Oncol. 2005. PMID: 15860854 Clinical Trial.
29 results